Objective: Considerable inaccuracy in estimates of HIV incidence has been a serious obstacle to the development of efficient HIV/AIDS prevention and interventions. Accurately distinguishing recent or incident infections from chronic infections enables one to monitor epidemics and evaluate the impact of HIV prevention/intervention trials. However, serological testing has not been able to realize these promises due to a number of critical limitations. Our study is to design a novel scheme of identifying incident infections in a highly accurate manner, based on the characteristics of HIV gene diversification within an infected individual.
Introduction
To assess how many people have been recently infected in a given area is an important task in HIV/AIDS trials including vaccination [2] , microbicides [3] , and other types of interventions [4] . Precise estimates of HIV incidence are essential to allocate HIV-related healthcare resources properly. In particular, incident estimates based on single blood draws from cross-sectional sampling of populations are in great need in resourcelimited settings.
The approximate window period of HIV incident infections is the first 1 year after transmission, which covers the eclipse phase and the stages of the Fiebig classification based on orderly appearance of viral RNA, viral antigens such as p24 and p31, and HIV-specific antibodies [5] . This period is characterized by rapid expansion and decline of viral RNA and gradual increase of HIV-specific antibody titers (Fig. 1a ). Current HIV incidence assays are based on the idea that antibody level or avidity rises in a predictable pattern during the first 4-6 months after transmission, eventually reaching a plateau that stays roughly constant for many years (Fig. 1a ). This approach includes the Serologic Testing Algorithm for Recent HIV Seroconversion (STARHS) [6, 7] , the BED capture enzyme immunoassay (BED) [8] , and the guanidine-based antibody avidity assay [9, 10] . However, the serologic assays are found to have a number of critical limitations including difficulty in the standardization, complication in the reproducibility, and strong dependence on the infecting virus clade [9, 11] . The limitations result in notable inaccuracy. The sensitivity, the proportion of incident infections correctly identified as incident, varies in the range of 42 and 100% with median of 89%, across 13 serologic assays [12] . The specificity, the proportion of chronic infections correctly identified as chronic, ranges from 49.5 to 100% with median of 86.8%. The tendency of the misclassification of long-standing infections as recent is pronounced among patients on antiretroviral treatment [12] . The substantial false recent rate is reported to be one of the limitations of the serologic assays as it results in the overestimation of incidence.
Here, we turn to utilizing recent advances in understanding early HIV infections [13, 14] and demonstrate that information derived from a set of HIV envelope genes obtained from a single blood sample can accurately distinguish incident infections from chronic ones. Single genome amplification (SGA) and sequencing of HIV envelope genes have shown that the majority of HIV infections originate from a single strain for both subtype B and subtype C infections [13] [14] [15] . Not all infections originate from a single founder strain. Two risk groups, men who have sex with men (MSM) and injection drug users (IDUs), show a high chance of being productively infected by more than one type of virus [16, 17] ; around 36% of MSM and around 60% of IDUs were found to be multivariant transmission. Fig. 1b illustrates the difference between single-variant and multivariant transmissions. As the infection propagates within an individual, as a consequence of the dynamic interplay between viral mutation and immune selection [18] , the HIV population diversifies (Fig. 1b ). This study suggests a novel assay with high levels of sensitivity and specificity based on the characteristics of HIV gene diversification originating from either a single-variant or multiple-variant founder strains.
Methods

Sequence data sources
The HIV env sequences of 182 incident and 43 chronic patients were collected from the published dataset in Refs [13] , [14] , and [17] . Geographic locations of the cohorts were United States, Trinidad, South Africa, Malawi, and Canada. All of the 5596 strains we analyzed were obtained by SGA and sequencing. The incident patients were substaged according to the Fiebig classification [5] : one participant was in stage I, 74 in stage II, 24 in stage III, 23 in stage IV, 44 in stage V, and 16 in stage VI. The routes of exposure include 92 heterosexual transmissions, 16 MSM participants, 12 IDU participants, and others of unknown route. Receiver operating characteristic analysis As in Ref [19] , the proportion of incident infections being correctly identified as incident, sensitivity, is plotted against the proportion of misclassification of chronic infections as incident, 1-specificity, as we incrementally change the putative Q 10 cutoff value. The optimal cutoff value is determined by the isocost line, maximizing the sum of sensitivity and specificity with equal consideration.
Results
We performed a meta-analysis by collecting 5596 previously published sequences generated by SGA-direct sequencing [20, 21] from 182 incident and 43 chronic cases [13, 14, 17] . The incident patients were classified as having recent HIV infections either by symptoms of acute infection or serologic evidence and the chronic patients were reported to have an infection period of longer than 1 year (see Methods for more). Incident infections were categorized into either single-variant or multivariant transmission [13, 14, 17] . The diversification can be quantified using the number of base differences between a pair of sequences, that is, their Hamming distance: HIV env diversity is the average number of base differences among all possible pairs of sequences sampled from a patient, divided by the sequence length. The env variance is the variance of the number of base differences among the sequences divided by the sequence length.
The high level of viral sequence diversity associated with multivariant transmissions suggests that a simple measure of the diversity or variance might misclassify early stages of individuals whose infection started with multiple founder viruses as being chronically infected. Indeed, as shown in Fig. 2a and b, the level of env diversity of around one third of the incident multivariant cases overlaps with those of chronic patients. Furthermore, the third quartile of the env variance of the incident patients with multiple founder strains is greater than the median env variance of the chronic patients. Neither envelope gene diversity nor variance provides clear discrimination between incident infections originating from multiple founder strains and chronic infections.
We sought an alternative signature in the Hamming distance distribution that discriminates chronic and incident infections. At an early phase, there should exist a fair number of identical or nearly identical sequences in each lineage of transmitted strain. Indeed, Fig. 3a shows that the first peak of the Hamming distance distribution of incident cases, including both single founder ( Fig. 3a top left) and multiple founder infections ( Fig. 3a top right) , is located in the region of very low Hamming distances, implying the presence of closely related sequences.
As infection progresses and the HIV population diversifies, the proportion of similar sequences should decline ( Fig. 1b) ; in fact, the proportion of identical sequences has been found to decrease exponentially as a function of time after infection [13, 15] . Fig. 3a confirms that chronic patients have a negligible frequency of sequence pairs in the region of low Hamming distance values, suggesting the absence of closely related sequences. We clarify this signature by quantifying the tail characteristics of the Hamming distance distribution; we measure the 10% quantile for Hamming distance, Q 10 that is, the Hamming distance value dividing the Hamming distance distribution into 10% below it and 90% above it. Fig. 3b highlights the difference between the distribution of the Q 10 statistics for the 182 incident infection samples and that for the 43 chronic samples.
Here the 182 incident patients include both 102 single founder and 80 multiple founder cases. The incident Q 10 distribution (red in Fig. 3b ), which includes both single and multiple founder infections, is visibly disparate from the chronic distribution (blue in Fig. 3b ).
The clear difference between the incident and chronic Q 10 distributions led us to devise a binary classification test to identify samples from incident infections as being significantly different from the population of chronic infections. If Q 10 is greater than the cutoff value Q 10 cutoff , the sample is judged as a chronic infection and otherwise the sample is scored as an incident infection. As with most binary classifications, there is a trade-off between specificity and sensitivity that is Genome-based HIV incidence assay Park et al. controlled by the choice of the threshold. The cutoff value of Q 10 cutoff is objectively determined from an analysis of the receiver operating characteristic (ROC) curve [22] . The isocost line designates Q 10 cutoff ¼ 7 as the optimal value. Whereas simple measures of viral diversity and variance fail to discriminate chronic samples from incident ones, the binary classification test statistically differentiates the two groups. All of the 43 chronic patients showed Q 10 values greater than the threshold of 7, indicating a specificity of 100%. Only five out of 182 incident patients had Q 10 values greater than the threshold; the measured sensitivity is 97.3% and the majority of the five misclassified patients were infected through intravenous drug use. These high levels of sensitivity and specificity convincingly suggest the possibility of using the tail characteristics of the Hamming distance distribution as a biomarker for identification of incident infections. Measuring Hamming distance distribution is advantageous because it can be determined from a single blood draw from each individual in crosssectional blood surveys.
Our biomarker is robust under changes of viral specific and host-specific factors such as the viral subtype, the viral load of participants, and the length and location of the sampled envelope gene sequences. Fig. 4a shows the ROC curve of the Q 10 distributions when we exclude the dataset of subtype C infections. The area under the ROC curve with subtype B infections only remained the same as that with both subtype B and C infections, 0.998, implying that the biomarker is not sensitive to the clade of the viral strains. The ROC curve with only subtype B infections provides a sensitivity of 95.6% and a specificity of 100% with Q 10 cutoff ¼ 7. This is presumably because the dynamics of early HIV diversification is not greatly affected by viral subtype. In contrast, the existing serologic assays have significantly different window periods of incident infections among subtype B and other subtypes [11] . Little association is observed between the biomarker and the viral load. Fig. 4b shows the scatter plot of Q 10 values and viral loads measured from both incident and chronic patients. The correlation coefficients were À0.04 for incident patients and 0.13 for chronic patients, suggesting that the biomarker is not sensitive to each patient's viral load.
We find that the sensitivity and specificity of the assay remain very high under the changes of either the length or region of the envelope gene. Although the changes in the incident Q 10 distribution by varying the length of env are minor, the mean of the chronic Q 10 distribution decreases substantially as the length of env decreases ( Fig. 4c ). Despite this dependence, we stress that the sensitivity and specificity are markedly high, 95.1% or greater regardless of whether we consider 500, 1000, 2000 base long env segments or full env, as we control Q 10 cutoff values objectively based on the ROC curve analysis (see Fig. 5a and 5b ). Our analysis suggests that read lengths of HIV env as short as 500 bases do not affect the accuracy of the assay. Chronic Q 10 distributions show a considerable amount of variation with the choice of the location within env. As Fig. 4d displays, the 500 base long segment of env encompassing the major portion of the V3 loop, HXB2 7125-7624, shows the greatest mean of Q 10 and the segment of HXB2 7625-8124 shows the smallest mean. We postulate that differing observed distributions imply that, in chronic infections, purifying selections keep certain sections of env quite conserved despite a long period of infection. The presence of purifying selections in chronic infection has been reported [23] . However, the impact of purifying selection does not appear to be strong enough to weaken the signature of chronic infection. The power of discrimination even in the least sensitive region (HXB2 7625-8124) is comparable to the power of the Genome-based HIV incidence assay Park et al. entire env; the sensitivity is 98.4% and the specificity is 97.7% with the optimal Q 10 cutoff ¼ 0; the 10% quantile of the Hamming distance distributions of 179 out of the 182 incident patients was 0, but only a single chronic patient had a 10% quantile value of 0. We conclude that our HIV incidence assay is robust to changes of the length and location of HIV env as summarized in Fig. 5 .
Discussion
We find that sequence similarity used as a biomarker has high specificity and sensitivity and is robust to viral and host-specific factors such as the clade of the viral strain, viral load, and the length and location of sequences in the HIV envelope gene. We found that a simple measure of the viral diversity or variance failed to distinguish chronically infected individuals from those infected with multiple founder viruses but who are at an early stage. This is due to the fact that distinct founder strains in multivariant transmissions caused increased Hamming distance diversity and variance (see Fig. 2 and Fig. 3a ). On the other hand, there still exists a tangible number of very closely related sequences within each lineage of the founder virus at incident stage, which yields lower Q 10 values than do individuals in chronic stage. Consequently, the 10% quantile of the Hamming distance distribution, instead of the mean or variance of the Hamming distance distribution, was found to be a robust measure for distinguishing incident infections, including multivariant transmissions, from chronic infections.
One foreseeable issue for the development of a genomebased HIV incidence assay is the decline in viral sequence diversity that occurs during the later stages of infection [24, 25] . This common phenomenon of diversity decline as the end point disease is approached implies that we cannot exclude the possibility that a sequencing-based assay might identify some individuals with late infection as having an incident infection. Sequences collected from patients with end point disease would be essential to examine this possibility at the population level. However, such late-stage patients should be identifiable based on clinical criteria by introducing additional measures such as CD4 þ T-cell count.
The datasets used in the present study were obtained by SGA and sequencing, which conventionally samples less than 100 sequences. On the other hand, deep sequencing [26] is capable of producing more than 10 000 reads from a single blood sample. The estimation of tail characteristics of a distribution such as Q 10 requires a substantially greater sample size than the estimation of central characteristics such as the mean or median. One of the limitations of the current deep sequencing platforms is that a relatively short read length (400-600 base long) is produced in comparison to SGA and Sanger sequencing. Our analysis suggests that short read lengths do not affect the accuracy of the assay, implying that data from deep sequencing methods could also be used to develop the assay. Caution would be needed in terms of sequencing errors and re-sampling issues of deep sequencing methods for future implementation.
Our study has demonstrated that a sequencing-based HIV incidence assay could be a very powerful tool for identifying incident infections in a highly accurate manner. The rapid decrease in the cost of DNA sequencing over decades suggests the potential of our assay to be cost-effective and widely adopted in clinical practice. More empirical data will be essential to further validate this new paradigm by examining the sensitivity of the assay to logistical factors. Our assay is advantageous as it is expected to designate incident infection or chronic infection from a single blood draw measure, not necessarily combining different measures and adopting multiassay algorithms.
